Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageMaravai LifeSciences Holdings, Inc. (also referred to in this document as “Maravai,” “we,” “us,” “our” or “the Company”) is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease. Our customers include biopharmaceutical companies, emerging biotech firms, life science research organizations, academic research institutions and diagnostics companies.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $65.6MThe company’s own SEC segment disclosure.
- United States$30.9M47%
- North America$24.6M38%
- EMEA$6.1M9%
- Asia Pacific$3.7M6%
- Latin And Central America$193.0K0%
Maravai LifeSciences Holdings, Inc. (MRVI) reported revenue of $66M in Q1 2026 (quarter ended Mar 31, 2026), up 41% from the same quarter a year earlier. That came with a gross margin of 51% and net loss of $3.7M. For the full year FY2025, revenue was $186M (−28% year on year) and net income −$131M. Its largest region in Jun 2026 was United States at $31M, 47% of the disclosed total, ahead of North America at 38%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.